Neurogranin in Alzheimer's Disease: Roles in synaptic function, pathology, and potential as a diagnostic biomarker

被引:0
作者
Bavaharini, Rajkumar [1 ]
Somala, Chaitanya Sree [2 ]
Saravanan, Konda Mani [2 ,3 ]
Anand, Thirunavukarasou [4 ]
机构
[1] Tamil Nadu Agr Univ, Ctr Plant Mol Biol & Biotechnol, Dept Plant Biotechnol, Coimbatore 641003, Tamil Nadu, India
[2] B Aatral Biosci Pvt Ltd, Bangalore 560091, Karnataka, India
[3] Bharath Inst Higher Educ & Res, Dept Biotechnol, Chennai 600073, Tamil Nadu, India
[4] Sri Ramachandra Inst Higher Educ & Res, Fac Clin Res, SRIIC Lab, Chennai 600116, Tamil Nadu, India
来源
AIMS MOLECULAR SCIENCE | 2024年 / 11卷 / 04期
关键词
neurogranin; Alzheimer's disease; biomarkers; synaptic dysfunction; cognitive decline; CEREBROSPINAL-FLUID; CALMODULIN; ASSOCIATION; EXPRESSION; DISORDERS; PROTEIN; IMPACT; BETA; TAU; CSF;
D O I
10.3934/molsci.2024020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Postsynaptic protein neurogranin (Ng), which plays a role in synaptic plasticity, learning, and memory, has been identified as the candidate biomarker of Alzheimer's disease (AD). Cortical Amyloid beta pathology seems to accelerate the onset of clinical symptoms; therefore, it is potentially valuable for early diagnosis of AD and therapeutic intervention. Synaptic pathology was shown to be an early feature of AD. Thus, proteins involved in synaptic function, such as Ng, are of great interest in studying the disease. Some prior human studies have found that Ng, a protein involved in the regulation of synaptic function, is present at greater levels in the cerebrospinal fluid of people with AD compared with those without the disease. High levels of neurogranin are associated with increased levels of synaptic vulnerability and decreased cognitive function in AD patients. This review, therefore, looked at the functionality of Ng in the brain, its association with other synaptic proteins, and its applicability as a diagnostic marker in AD. This study, therefore, sought to expand the knowledge on Ng changes in AD as it relates to synaptic dysfunction and enhanced the search for a better diagnostic and therapeutic approach.
引用
收藏
页码:330 / 350
页数:21
相关论文
共 91 条
  • [1] Candidate biomarkers in psychiatric disorders: state of the field
    Abi-Dargham, Anissa
    Moeller, Scott J.
    Ali, Farzana
    DeLorenzo, Christine
    Domschke, Katharina
    Horga, Guillermo
    Jutla, Amandeep
    Kotov, Roman
    Paulus, Martin P.
    Rubio, Jose M.
    Sanacora, Gerard
    Veenstra-VanderWeele, Jeremy
    Krystal, John H.
    [J]. WORLD PSYCHIATRY, 2023, 22 (02) : 236 - 262
  • [2] Is plasticity of synapses the mechanism of long-term memory storage?
    Abraham, Wickliffe C.
    Jones, Owen D.
    Glanzman, David L.
    [J]. NPJ SCIENCE OF LEARNING, 2019, 4 (01)
  • [3] Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer's Disease
    Agnello, Luisa
    Lo Sasso, Bruna
    Vidali, Matteo
    Scazzone, Concetta
    Piccoli, Tommaso
    Gambino, Caterina Maria
    Bivona, Giulia
    Giglio, Rosaria Vincenza
    Ciaccio, Anna Maria
    La Bella, Vincenzo
    Ciaccio, Marcello
    [J]. DIAGNOSTICS, 2021, 11 (12)
  • [4] Neurogranin as a Novel Biomarker in Alzheimer's Disease
    Agnello, Luisa
    Gambino, Caterina Maria
    Lo Sasso, Bruna
    Bivona, Giulia
    Milano, Salvatore
    Ciaccio, Anna Maria
    Piccoli, Tommaso
    La Bella, Vincenzo
    Ciaccio, Marcello
    [J]. LABORATORY MEDICINE, 2021, 52 (02) : 188 - 196
  • [5] 2023 Alzheimer's disease facts and figures
    不详
    [J]. ALZHEIMERS & DEMENTIA, 2023, 19 (04) : 1598 - 1695
  • [6] Calcium Signalling in Heart and Vessels: Role of Calmodulin and Downstream Calmodulin-Dependent Protein Kinases
    Beghi, Sofia
    Furmanik, Malgorzata
    Jaminon, Armand
    Veltrop, Rogier
    Rapp, Nikolas
    Wichapong, Kanin
    Bidar, Elham
    Buschini, Annamaria
    Schurgers, Leon J.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [7] Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease
    Bergstrom, Sofia
    Remnestal, Julia
    Yousef, Jamil
    Olofsson, Jennie
    Markaki, Ioanna
    Carvalho, Stephanie
    Corvol, Jean-Christophe
    Kultima, Kim
    Kilander, Lena
    Lowenmark, Malin
    Ingelsson, Martin
    Blennow, Kaj
    Zetterberg, Henrik
    Nellgard, Bengt
    Brosseron, Frederic
    Heneka, Michael T.
    Bosch, Beatriz
    Sanchez-Valle, Raquel
    Manberg, Anna
    Svenningsson, Per
    Nilsson, Peter
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2021, 8 (07): : 1456 - 1470
  • [8] Early Adverse Experiences and the Developing Brain
    Bick, Johanna
    Nelson, Charles A.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 (01) : 177 - 196
  • [9] CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD
    Blennow, Kaj
    Diaz-Lucena, Daniela
    Zetterberg, Henrik
    Villar-Pique, Anna
    Karch, Andre
    Vidal, Enric
    Hermann, Peter
    Schmitz, Matthias
    Abizanda, Isidro Ferrer
    Zerr, Inga
    Llorens, Franc
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (08) : 846 - 853
  • [10] Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
    Bouwman, Femke H.
    Frisoni, Giovanni B.
    Johnson, Sterling C.
    Chen, Xiaochun
    Engelborghs, Sebastiaan
    Ikeuchi, Takeshi
    Paquet, Claire
    Ritchie, Craig
    Bozeat, Sasha
    Quevenco, Frances-Catherine
    Teunissen, Charlotte
    [J]. ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2022, 14 (01)